Global Parallel Artificial Membrane Permeability Assay 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI02256558

Publication Date:

March 3, 2025

Pages:

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

IT Services [2]

Software [3]

Computing & Electronics [4]

Description:

The global Parallel Artificial Membrane Permeability Assay market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The Parallel Artificial Membrane Permeability Assay (PAMPA) is a high-throughput screening method used in drug discovery to predict the passive permeability of a compound across biological membranes. It is a cost-effective and rapid alternative to traditional in vitro permeability assays.
PAMPA involves the use of an artificial lipid membrane, typically made of a phospholipid bilayer, which mimics the properties of biological membranes. The compound of interest is applied to one side of the membrane, and the rate at which it crosses the membrane is measured. The rate of permeation is determined by factors such as the compound"s lipophilicity, molecular size, and charge.
The PAMPA assay can be performed in a parallel format, allowing multiple compounds to be tested simultaneously. It is commonly used in early stages of drug discovery to assess the potential for a compound to be absorbed into the bloodstream, cross the blood-brain barrier, or penetrate other biological barriers.
The results obtained from PAMPA can be used to prioritize compounds for further testing and optimization, as well as to estimate the bioavailability and pharmacokinetic properties of a compound.
United States market for Parallel Artificial Membrane Permeability Assay is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Parallel Artificial Membrane Permeability Assay is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Parallel Artificial Membrane Permeability Assay is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Parallel Artificial Membrane Permeability Assay players cover Cyprotex, Creative Biolabs, Admescope, Creative Bioarray, Enamine, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淧arallel Artificial Membrane Permeability Assay Industry Forecast鈥� looks at past sales and reviews total world Parallel Artificial Membrane Permeability Assay sales in 2024, providing a comprehensive analysis by region and market sector of projected Parallel Artificial Membrane Permeability Assay sales for 2025 through 2031. With Parallel Artificial Membrane Permeability Assay sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Parallel Artificial Membrane Permeability Assay industry.
This Insight Report provides a comprehensive analysis of the global Parallel Artificial Membrane Permeability Assay landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Parallel Artificial Membrane Permeability Assay portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Parallel Artificial Membrane Permeability Assay market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Parallel Artificial Membrane Permeability Assay and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Parallel Artificial Membrane Permeability Assay.
This report presents a comprehensive overview, market shares, and growth opportunities of Parallel Artificial Membrane Permeability Assay market by product type, application, key players and key regions and countries.
Segmentation by Type:
Caco-2 Cultures
Gastrointestinal Tract
Blood鈥揵rain Barrier
Skin
Segmentation by Application:
Drug Discovery
Cosmetic Research
Toxicology Research
Drug Delivery Research
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Cyprotex
Creative Biolabs
Admescope
Creative Bioarray
Enamine
Sygnature Discovery
Aurigene Pharmaceutical Services

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Parallel Artificial Membrane Permeability Assay 麻豆原创 Size (2020-2031)
2.1.2 Parallel Artificial Membrane Permeability Assay 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Parallel Artificial Membrane Permeability Assay by Country/Region (2020, 2024 & 2031)
2.2 Parallel Artificial Membrane Permeability Assay Segment by Type
2.2.1 Caco-2 Cultures
2.2.2 Gastrointestinal Tract
2.2.3 Blood鈥揵rain Barrier
2.2.4 Skin
2.3 Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Type
2.3.1 Parallel Artificial Membrane Permeability Assay 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Parallel Artificial Membrane Permeability Assay 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Parallel Artificial Membrane Permeability Assay Segment by Application
2.4.1 Drug Discovery
2.4.2 Cosmetic Research
2.4.3 Toxicology Research
2.4.4 Drug Delivery Research
2.5 Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Application
2.5.1 Parallel Artificial Membrane Permeability Assay 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Parallel Artificial Membrane Permeability Assay 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Player
3.1 Parallel Artificial Membrane Permeability Assay 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Parallel Artificial Membrane Permeability Assay Revenue by Player (2020-2025)
3.1.2 Global Parallel Artificial Membrane Permeability Assay Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Parallel Artificial Membrane Permeability Assay Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Parallel Artificial Membrane Permeability Assay by Region
4.1 Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Region (2020-2025)
4.2 Global Parallel Artificial Membrane Permeability Assay Annual Revenue by Country/Region (2020-2025)
4.3 Americas Parallel Artificial Membrane Permeability Assay 麻豆原创 Size Growth (2020-2025)
4.4 APAC Parallel Artificial Membrane Permeability Assay 麻豆原创 Size Growth (2020-2025)
4.5 Europe Parallel Artificial Membrane Permeability Assay 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Parallel Artificial Membrane Permeability Assay 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Country (2020-2025)
5.2 Americas Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Type (2020-2025)
5.3 Americas Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Region (2020-2025)
6.2 APAC Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Type (2020-2025)
6.3 APAC Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Country (2020-2025)
7.2 Europe Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Type (2020-2025)
7.3 Europe Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Parallel Artificial Membrane Permeability Assay by Region (2020-2025)
8.2 Middle East & Africa Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Parallel Artificial Membrane Permeability Assay 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Parallel Artificial Membrane Permeability Assay 麻豆原创 Forecast
10.1 Global Parallel Artificial Membrane Permeability Assay Forecast by Region (2026-2031)
10.1.1 Global Parallel Artificial Membrane Permeability Assay Forecast by Region (2026-2031)
10.1.2 Americas Parallel Artificial Membrane Permeability Assay Forecast
10.1.3 APAC Parallel Artificial Membrane Permeability Assay Forecast
10.1.4 Europe Parallel Artificial Membrane Permeability Assay Forecast
10.1.5 Middle East & Africa Parallel Artificial Membrane Permeability Assay Forecast
10.2 Americas Parallel Artificial Membrane Permeability Assay Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.2.2 Canada 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.2.3 Mexico 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.2.4 Brazil 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.3 APAC Parallel Artificial Membrane Permeability Assay Forecast by Region (2026-2031)
10.3.1 China Parallel Artificial Membrane Permeability Assay 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.3.3 Korea 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.3.4 Southeast Asia 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.3.5 India 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.3.6 Australia 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.4 Europe Parallel Artificial Membrane Permeability Assay Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.4.2 France 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.4.3 UK 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.4.4 Italy 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.4.5 Russia 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.5 Middle East & Africa Parallel Artificial Membrane Permeability Assay Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.5.2 South Africa 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.5.3 Israel 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.5.4 Turkey 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
10.6 Global Parallel Artificial Membrane Permeability Assay Forecast by Type (2026-2031)
10.7 Global Parallel Artificial Membrane Permeability Assay Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Parallel Artificial Membrane Permeability Assay Forecast
11 Key Players Analysis
11.1 Cyprotex
11.1.1 Cyprotex Company Information
11.1.2 Cyprotex Parallel Artificial Membrane Permeability Assay Product Offered
11.1.3 Cyprotex Parallel Artificial Membrane Permeability Assay Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 Cyprotex Main Business Overview
11.1.5 Cyprotex Latest Developments
11.2 Creative Biolabs
11.2.1 Creative Biolabs Company Information
11.2.2 Creative Biolabs Parallel Artificial Membrane Permeability Assay Product Offered
11.2.3 Creative Biolabs Parallel Artificial Membrane Permeability Assay Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Creative Biolabs Main Business Overview
11.2.5 Creative Biolabs Latest Developments
11.3 Admescope
11.3.1 Admescope Company Information
11.3.2 Admescope Parallel Artificial Membrane Permeability Assay Product Offered
11.3.3 Admescope Parallel Artificial Membrane Permeability Assay Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Admescope Main Business Overview
11.3.5 Admescope Latest Developments
11.4 Creative Bioarray
11.4.1 Creative Bioarray Company Information
11.4.2 Creative Bioarray Parallel Artificial Membrane Permeability Assay Product Offered
11.4.3 Creative Bioarray Parallel Artificial Membrane Permeability Assay Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Creative Bioarray Main Business Overview
11.4.5 Creative Bioarray Latest Developments
11.5 Enamine
11.5.1 Enamine Company Information
11.5.2 Enamine Parallel Artificial Membrane Permeability Assay Product Offered
11.5.3 Enamine Parallel Artificial Membrane Permeability Assay Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Enamine Main Business Overview
11.5.5 Enamine Latest Developments
11.6 Sygnature Discovery
11.6.1 Sygnature Discovery Company Information
11.6.2 Sygnature Discovery Parallel Artificial Membrane Permeability Assay Product Offered
11.6.3 Sygnature Discovery Parallel Artificial Membrane Permeability Assay Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Sygnature Discovery Main Business Overview
11.6.5 Sygnature Discovery Latest Developments
11.7 Aurigene Pharmaceutical Services
11.7.1 Aurigene Pharmaceutical Services Company Information
11.7.2 Aurigene Pharmaceutical Services Parallel Artificial Membrane Permeability Assay Product Offered
11.7.3 Aurigene Pharmaceutical Services Parallel Artificial Membrane Permeability Assay Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Aurigene Pharmaceutical Services Main Business Overview
11.7.5 Aurigene Pharmaceutical Services Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.